Radiation, Chemotherapy or Combined Modality Therapy
in Adjuvant Treatment for Stage III Endometrial
Carcinoma in Lower Southern Thailand: Disease
Recurrence and Overall Survival
Aroontorn Pichatechaiyoot MD*, Rakchai Buhachat MD*,
Sathana Boonyapipat MD*, Kanet Kanjanapradit MD**
Affiliation :
* Department of Obstetrics and Gynecology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla Thailand
** Department of Pathology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand
Objective : To survey disease-free survival (DFS) and overall survival (OS) of patients with stage III endometrial carcinoma
treated with post-operative radiation and/or chemotherapy
Material and Method: The medical records of patients with surgical stage III endometrial carcinoma, and receiving adjuvant
treatment between January 2003 and December 2012 were reviewed. DFS and OS were analyzed using the Kaplan-Meier
method and Cox proportional hazards model.
Results : Of the 54 eligible patients, 61% underwent radiation, 19% chemotherapy, and 20% chemotherapy with radiation.
The median DFS was 36.7 months. The 3-year DFS and OS was 51.9% (95% CI 36.3-74.1%) and 70.6% (95% CI 57.4-86.8%),
respectively. There was no significant difference in DFS and OS among treatment groups. Cox regression analysis showed
grade 2-3 tumors and menopause were associated with poor DFS and OS.
Conclusion : The DFS and OS in stage III endometrial carcinoma receiving postoperative adjuvant therapy were quite good
and were not different among radiation therapy, chemotherapy, and combined treatment groups. The multi-center randomized
prospective study was needed to determine the standard modality.
Keywords : Endometrial carcinoma, Adjuvant therapy, Radiation, Chemotherapy
All Articles
Download